Press release content from Business Wire. The AP news staff was not involved in its creation.

NeoGenomics, Inc. (NEO) Investor Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline in Class Action Against NeoGenomics, Inc.

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 19, 2022 GMT

SAN DIEGO--(BUSINESS WIRE)--Dec 19, 2022--

The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, for violations of the Securities Exchange Act of 1934. NeoGenomics provides cancer tests and testing services to doctors, clinics, hospitals, and pharmaceutical companies. Among the Company’s portfolio of tests are next generation sequencing (“NGS”) tests.

What Now: Similarly situated shareholders may be eligible to participate in the class action against NeoGenomics, Shareholders who want to act as lead plaintiff for the class must file their papers by February 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.


All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: NeoGenomics, Inc. (NEO) Misled Investors Regarding the Quality of its Tests and Ability to Fix Costs

According to the complaint, during the class period, defendants misrepresented to investors that it had a “comprehensive menu” of cancer tests that positioned it as a “one-stop-shop” for pathologists that needed cancer testing. Defendants further asserted that NeoGenomics could “leverage” the supposedly “fixed cost” structure of its business to improve profitability as revenue increased.

In contrast: (i) NeoGenomics was anything but a “one-stop-shop” for cancer testing because it did not offer the most technologically advanced NGS tests, which led to a significant decrease in revenue as current and prospective customers went elsewhere for their testing needs; (ii) the Company’s costs were not fixed because NeoGenomics needed to hire additional employees to process more complex customized testing demanded by customers utilizing the Company’s outdated portfolio of tests, leading to operational challenges, decreased lab efficiency, and increased testing turnaround times; and (iii) NeoGenomics violated federal healthcare laws and regulations related to fraud, waste, and abuse.


As the truth was revealed between November 4, 2021 and April 27, 2022, NeoGenomics stock declined. While the stock was trading at $46.53 per share on November 4, 2021, it now trades at just $11.60 per share.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NeoGenomics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.


Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on

CONTACT: Contact:

Aaron Dumas

Robbins LLP

5060 Shoreham Pl., Ste. 300

San Diego, CA 92122

(800) 350-6003




Copyright Business Wire 2022.

PUB: 12/19/2022 11:01 AM/DISC: 12/19/2022 11:02 AM